Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bio-Rad Pasteur

Division of Bio-Rad Laboratories Inc.

Latest From Bio-Rad Pasteur

How Big Can Bio-Rad Get?

Bio-Rad's having a great year, thanks to its presence in the fast-growing life sciences business of protein analysis, and its surprise success with a test for bovine spongiform encephalopathy (BSE). Founder and CEO David Schwartz built the business based on a mix of eclectic product lines into an $800 million force in life sciences and clinical diagnostics. But as he nears 80, the company is grappling with succession issues, as well as a sense that it needs to better integrate its disparate businesses.
BioPharmaceutical Medical Device

Nous Voici! Sanofi's Leap to the World Stage

Still as French as they come, Sanofi's extraordinary international success--its P/E and growth rate are among the industry's highest--has been due to two factors. The first is its productive research group, which has eschewed most biotech fashions in favor of a conservative, small-molecule, therapeutically focused R&D program. The second has been its joint venture with Bristol-Myers on two of its most important products, a joint venture which allowed Sanofi, in a protected fashion, to learn to compete internationally against the most powerful pharmaceutical marketers in the world. If the company has an Achilles' heel, it is the francocentrism of its marketing and development, and perhaps research as well.
BioPharmaceutical Strategy

For Diagnostics, a Hum-Drum 2000

The diagnostics industry's overall flat growth in 2000 belies individual triumphs and setbacks and shifts in market share.
Medical Device

Betting on Beads

Four year old Luminex appears to be in the right place at the right time, but it faces increasing competition in a confusing field. The company has, in only a few short years, launched two generations of products, completed a successful IPO, and captured the attention of life scientists, who are scrambling for inexpensive, fast tools that can do genetic and proteomic analysis. Luminex has a simple-to-use multiplexing platform, which is flexible and inexpensive enough to be easily adapted to fields as diverse as genomics and clinical diagnostics.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Sanofi Diagnostics Pasteur
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Bio-Rad Laboratories Inc.
  • Senior Management
  • Contact Info
  • Bio-Rad Pasteur
    Phone: (33)
    Marnes-La Coquette,